Literature DB >> 3747418

Fructose-induced hyperlactemia in hyperosmolar syndromes.

W Druml, G Kleinberger, K Lenz, A Laggner, B Schneeweiss.   

Abstract

Severe hyperlactemia of 8.7, 8.6 and 7.9 mmol/l, respectively, developed in three patients with hyperosmolar syndromes (two hypernatremic, 417 and 415 mosmol/kg H2O; one hyperglycemic 437 mosmol/kg H2O) during rehydration treatment with 5% fructose in water (fructose dosage 0.5 g/kg body wt. per hour). After resolution of the electrolyte disturbances, the infusion of fructose at the same dosage increased the plasma lactate concentration in two of the patients to 4.9 and 4.0 mmol/l, indicating near normalization of hepatic lactate utilization. Thus, in addition to peripheral insulin resistance and decreased muscular glucose utilization, the hyperosmolar state is associated with a reduced tolerance to fructose. This is most likely due to an osmolality-dependent impairment of hepatic gluconeogenesis. In rehydration therapy for hyperosmolar syndromes, fructose-containing infusion solutions should no longer be used.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3747418     DOI: 10.1007/bf01735263

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  11 in total

1.  Severe hyperglycemia: effects of rehydration on endocrine derangements and blood glucose concentration.

Authors:  W Waldhäusl; G Kleinberger; A Korn; R Dudczak; P Bratusch-Marrain; P Nowotny
Journal:  Diabetes       Date:  1979-06       Impact factor: 9.461

2.  Hereditary fructose intolerance. An inborn defect of hepatic fructose-1-phosphate splitting aldolase.

Authors:  E R FROESCH; H P WOLF; H BAITSCH; A PRADER; A LABHART
Journal:  Am J Med       Date:  1963-02       Impact factor: 4.965

3.  Dangers of intravenous fructose.

Authors:  H F Woods; K G Alberti
Journal:  Lancet       Date:  1972-12-23       Impact factor: 79.321

4.  [Infusion dose limits of glucose, sorbitol, fructose xylitol and their mixtures (author's transl)].

Authors:  G Berg; F Matzkies; H Bickel
Journal:  Dtsch Med Wochenschr       Date:  1974-03-29       Impact factor: 0.628

5.  Lactic acidosis complicating liver failure after intravenous fructose.

Authors:  G M Craig; C W Crane
Journal:  Br Med J       Date:  1971-10-23

6.  [Hypernatraemic hyperosmolar syndrome (author's transl)].

Authors:  P Bratusch-Marrain; G Kleinberger; M Pichler
Journal:  Dtsch Med Wochenschr       Date:  1981-02-13       Impact factor: 0.628

7.  [The metabolism of the splanchnic region under the influence of fructose].

Authors:  G Dietze; M Wicklmayr; K D Hepp; J Grunst; G Stiegler; H Mehnert
Journal:  Infusionstherapie       Date:  1974-10

8.  Impairment of insulin-mediated glucose metabolism by hyperosmolality in man.

Authors:  P R Bratusch-Marrain; R A DeFronzo
Journal:  Diabetes       Date:  1983-11       Impact factor: 9.461

Review 9.  [Influence of insulinfree rehydration on diabetic derangements (author's transl)].

Authors:  G Kleinberger
Journal:  Wien Klin Wochenschr       Date:  1980-09-12       Impact factor: 1.704

10.  An assessment of insulin action in hyperosmolar hyperglycemic nonketotic diabetic patients.

Authors:  N R Rosenthal; E J Barrett
Journal:  J Clin Endocrinol Metab       Date:  1985-03       Impact factor: 5.958

View more
  3 in total

1.  Rising serum sodium levels are associated with a concurrent development of metabolic alkalosis in critically ill patients.

Authors:  Gregor Lindner; Christoph Schwarz; Heidelinde Grüssing; Nikolaus Kneidinger; Andreas Fazekas; Georg-Christian Funk
Journal:  Intensive Care Med       Date:  2012-11-17       Impact factor: 17.440

2.  Incidence and prognosis of dysnatremias present on ICU admission.

Authors:  Georg-Christian Funk; Gregor Lindner; Wilfred Druml; Barbara Metnitz; Christoph Schwarz; Peter Bauer; Philipp G H Metnitz
Journal:  Intensive Care Med       Date:  2009-10-22       Impact factor: 17.440

Review 3.  The importance of the ionic product for water to understand the physiology of the acid-base balance in humans.

Authors:  María M Adeva-Andany; Natalia Carneiro-Freire; Cristóbal Donapetry-García; Eva Rañal-Muíño; Yosua López-Pereiro
Journal:  Biomed Res Int       Date:  2014-04-30       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.